Presenter: Jamie Corroon, ND, MPH

Original Date: October 21, 2018

The role of the endocannabinoid system in both physiological and pathophysiological function of the gastrointestinal tract is relatively unknown. Pharmacokinetic studies shed light on the metabolism and bioavailability of exogenous cannabinoids. Preclinical and clinical trials continue to explore the utility of using cannabinoids as therapeutic agents for gastrointestinal disorders. This presentation elucidates the key functions of the endocannabinoid system in maintaining gut function. It also summarizes existing evidence for using cannabinoids to treat GI disorders.

Pharmaceuticals covered:

• Cannabidiol
• Nabiximols
• Dronabinol
• Nabilone

1.0 General CEUs approved by OBNM